Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Intangibles (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Intangibles for 14 consecutive years, with $479.5 million as the latest value for Q4 2025.

  • Quarterly Intangibles fell 11.5% to $479.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $479.5 million through Dec 2025, down 11.5% year-over-year, with the annual reading at $479.5 million for FY2025, 11.5% down from the prior year.
  • Intangibles hit $479.5 million in Q4 2025 for Ani Pharmaceuticals, down from $499.8 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $569.8 million in Q3 2024 to a low of $4.3 million in Q2 2023.
  • Historically, Intangibles has averaged $291.5 million across 5 years, with a median of $245.2 million in 2022.
  • Biggest five-year swings in Intangibles: tumbled 98.41% in 2023 and later soared 4157.63% in 2024.
  • Year by year, Intangibles stood at $294.1 million in 2021, then dropped by 14.45% to $251.6 million in 2022, then fell by 16.94% to $209.0 million in 2023, then soared by 159.24% to $541.8 million in 2024, then dropped by 11.5% to $479.5 million in 2025.
  • Business Quant data shows Intangibles for ANIP at $479.5 million in Q4 2025, $499.8 million in Q3 2025, and $15.8 million in Q2 2025.